BBS news announced today that the drugs advisory body in the UK, the UK National Institute for Health and Clinical Excellence, and NHS England will trial a new payment model that means pharmaceutical companies that development new antibiotics will be paid for drugs based on how valuable the medicines are to the NHS, rather than by the quantity of drugs sold.
Health Secretary Matt Hancock, launched the government’s 20-year vision at the World Economic Forum at Davos, Switzerland. “Antimicrobial resistance is as big a danger to humanity as climate change or warfare. That’s why we need an urgent global response”, he argues.
Traditionally, drugs companies are paid for the amount of antibiotics they sell. This has led to a “market failure” where companies are incentivised to sell existing antibiotics, rather than innovate and develop new treatments for infections where they are most needed.
By changing to a model where companies are paid based on how valuable the medicines are to the NHS, the UK government anticipates that companies will start to invest in the development of new, high-priority drugs.
Developing such new, high-priority drugs to fight bacterial infections is precisely what Madam Therapeutics has been doing since its start in 2011. The executive board from Madam Therapeutics welcomes this critical step by the UK government, and hopes that other European and other governments will follow soon.
Source: BBC News